Skip to Content

Medtronic PLC MDT

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Medtronic Begins Fiscal 2022 in Solid Fashion; No Change to Our Fair Value Estimate

Debbie S. Wang Senior Equity Analyst

Analyst Note

| Debbie S. Wang |

Medtronic got off to a solid start in fiscal first quarter that featured a nice recovery from the relatively weak prior-year period. We’re holding steady on our fair value estimate as these early results are generally consistent with our full-year projections. Medtronic’s atypical fiscal quarter timing, which includes July, provides a better peek into how the rise of the Delta variant has damped procedure volume growth as the summer unfolded. Thus far, it appears the effect has been felt most strongly in certain U.S. geographies that have been characterized by low vaccination rates but has had a modest impact on the firm overall. Management expects this pandemic pressure on volume to peak in September, and we concur based on how the Delta variant has played out in the U.K. and India. Despite these near-term speedbumps, we remain confident in Medtronic’s wide economic moat. We were pleased to see R&D investment accelerate in first quarter, which should continue through the second quarter. Medtronic’s ability to increase R&D spending at this scale allows it to support significant pipeline programs that reinforce the wide moat and which we expect will drive future growth, including renal denervation and extravascular implantable cardioverter defibrillators.

Read Full Analysis

Company Profile

Business Description

One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.

Lower Hatch Street, 20 On Hatch
Dublin, 2, Ireland
T +353 14381700
Sector Healthcare
Industry Medical Devices
Most Recent Earnings Jul 31, 2021
Fiscal Year End Apr 30, 2022
Stock Type
Employees 90,000


Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.